Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Characterization of EGFR mutant NSCLC transformed to SCLC (n=45).
70% received EP alone, 23% had EP combo (IO/TKI). Combo PFS 7.5m vs 2.8m (many confounders). DLL3+ in 88%, B7-H3+ in 67% but prior reports show poor RR to tarlatamab. ADCs here?”
Title: EGFR-Mutant Non-Small-Cell Lung Cancer with Small Cell Transformation: Clinicopathological Features, Treatment Landscape, and Biomarker Profiles
Authors: Chi-Lu Chiang, Ying-Ting Liao, Yi-Chen Yeh, Ruei-Lin Sun, Hsu-Ching Huang, Yung-Hung Luo, Chia-I Shen, Heng-Sheng Chao, Yen-Han Tseng, Tsu-Hui Shiao, Ruihong Wang, Haitao Wang, David S. Schrump, Yuh-Min Chen
Read the full article.
You can also read:
